Table 2 Study methodology and procedural specifications of included studies.
Author (Year) | Marin (2021)a [32] | Scalise (2020)b [31] | Ott (2019) [30] | Prasad (2019) [29] | Hameed (2017) [28] | Hering (2017) [27] | Hoye (2017) [22] | Kiuchi (2015) [26] | Ott (2015) [25] | Schlaich (2013) [24] | Hering (2012) [23] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inclusion Criteria | 1) OSBP > 140 despite being treated with ≥3 anti-HTN medication (including a diuretic) | 1) Long-term haemodialysis 2) OBP ≥ 140/90 despite being treated with ≥3 anti-HTN medication (including a diuretic) | 1) eGFR<15 2) 4-weeks of stable haemodialysis 3) 24-hour ABP ≥ 135/85, uncontrolled, on 4 weeks of stable treatment (at least three anti-HTN medications) | 1) OSBP > 140 despite being treated with ≥3 anti-HTN medication (including a diuretic) | 1) eGFR between 15–44 2) OSBP ≥ 140 despite being treated with ≥3 anti-HTN medication | 1) eGFR≤60 2) OBP > 140/90 despite being treated with ≥3 anti-HTN medication (including a diuretic if tolerated) | 1) Dialysis therapy for at least 3 months 2) OBP > 140/90 despite anti-HTN medication | 1) eGFR between 15- 89 (patients with eGFR >60 were required to have microalbuminuria) 2) OSBP ≥ 160 despite being treated with ≥3 anti-HTN medication (including a diuretic) | 1) OBP ≥ 140/90 despite being treated with ≥3 anti-HTN medication (including a diuretic) | 1) OBP > 140/90, despite being treated with ≥3 anti-HTN medication | NR | |
CKD Stage | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | |
3 | 47.6% (10) | 0 | 0 | 68.0% (17) | Patients were stage 3 and 4 | Patients were stage 3, 4 and 5 | 0 | 6 | Patients were stage 3 and 4 | 0 | Patients were stage 3 and 4 | |
4 | 33.3% (7) | 0 | 0 | 32.0% (8) | Patients were stage 3 and 4 | Patients were stage 3, 4 and 5 | 0 | 5 | Patients were stage 3 and 4 | 0 | Patients were stage 3 and 4 | |
5 | 19.0% (4) | 100% (12) | 100% (6) | 0 | 0 | Patients were stage 3, 4 and 5 | 100% (9) | 0 | 0 | 100% (9) | 0 | |
% Dialysis | 19.0% (4)c | 100% (12) | 100% (6) | 0 | 0 | NR | 100% (9) | 0 | 0 | 100% (9) | NR | |
Dialysis Modality | Haemodialysis | Haemodialysis | Haemodialysis | NA | NA | NR | Haemodialysis (n = 6), Peritoneal (n = 3) | NA | NA | Haemodialysis | NR | |
RDN Method | Symplicity Flex (n = 4), Symplicity Spyral (n = 17) | Bilateral (n = 11), Unilateral (n = 1, nephrectomy): Symplicity Spyral (n = 8), EnligHTN (n = 4) | Bilateral: Symplicity Flex | Unilateral (n = 4) Bilateral (n = 21): Symplicity | Symplicity flex or Symplicity Spyral | Bilateral: Symplicity | Multipolar: EnligHTN | AlCath Flux eXtra Gold Full Circle 2708 | Symplicity Flex | Bilateral: Symplicity Flex | Bilateral: Symplicity | |
Number of Ablations | 32.5 ± 15.6 | 28 ± 4.7 | Left: 6.2 ± 4.7 Right: 4.5 ± 0.95 | 4 to 6 ablations on each side | 11.3 ± 2.4 | 12.9 ± 3.3 | Left: 4 Right: 4 | Left: 9 ± 3 (5–14) Right: 9 ± 3 (4–14) | ≥4 | 10.2 ± 3.0 | 9.9 ± 1.5 | |
Drug Adherence Assessment | Direct Questioning | Direct Questioning | NA | NA | NR | Direct Questioning | NR | Review per F/U visit | Urine sampling at 6-month F/U (n = 17) | NR | Review per F/U visit | |
